Researchers have long been intrigued by the complex interplay between the brain’s serotonergic system—one of the primary targets of psilocybin—and the regulation of feeding and energy homeostasis. Serotonin is well-known not only for its role in mood modulation but also for its pivotal influence over appetite and metabolic rate. Psilocybin, acting as a potent serotonin receptor agonist, especially at the 5-HT2A receptor subtype, triggers a cascade of neural effects, many of which remain underexplored in the context of metabolism. This study fills a crucial gap by systematically characterizing how acute psilocybin administration impacts food intake and energy expenditure, along with mapping persistent long-term outcomes following single and repeated exposures.

The experiment was meticulously designed using murine models to allow fine-grained physiological monitoring alongside behavioral assays. Initially, psilocybin was administered intraperitoneally at doses reflecting psychoactive ranges relative to human consumption. Researchers recorded immediate effects on food consumption, noting a significant suppression of appetite within the first 24 hours. This anorectic effect coincides with activation of central serotonergic circuits that communicate satiety signals, supporting prior hypotheses that psychedelics can acutely curb feeding behavior through neuromodulation.

Crucially, beyond this short-term reduction in eating, the study delved into longitudinal analyses, tracking mice for weeks post-treatment to observe enduring changes. Remarkably, psilocybin-treated animals exhibited sustained alterations in energy balance physiology—manifested as stabilized body weights despite normalized food intake. Metabolic cages revealed enhanced energy expenditure through increased locomotor activity and thermogenesis, suggesting that psilocybin writes a persistent “metabolic tune” that elevates baseline caloric burn. These findings underscore a dual mechanism by which psilocybin may recalibrate energy homeostasis: immediately dampening appetite and subsequently amplifying metabolic rate.

Molecular investigations provided deeper mechanistic insight. Transcriptomic profiling of hypothalamic tissue highlighted significant modulation of genes implicated in appetite regulation, lipid metabolism, and mitochondrial function. Notably, expression of neuropeptides such as pro-opiomelanocortin (POMC), an anorexigenic factor, was upregulated, whereas orexigenic neuropeptides like neuropeptide Y (NPY) were suppressed. Concurrently, markers of mitochondrial biogenesis and oxidative phosphorylation showed increased activity, paralleling enhanced energy expenditure measurements. These data illustrate that psilocybin invokes a broad reprogramming of metabolic gene networks, potentially via epigenetic mechanisms that warrant further exploration.

Behaviorally, treated mice displayed subtle yet significant changes in feeding patterns, with reduced meal frequency but preserved meal size, implying modulation at the level of hunger signaling rather than satiety. This nuanced alteration indicates that psilocybin may rewire neural circuitry governing the motivational aspects of feeding without compromising the ability to consume in response to deprivation. Interestingly, these behavioral changes co-occurred with reduced anxiety-like phenotypes as measured by standard rodent tests, aligning with psilocybin’s established psychoactive anxiolytic effects. Such interplay between mood, anxiety, and feeding behaviors highlights the compound’s potential for integrated neuropsychiatric-metabolic interventions.

The significance of this research extends well beyond rodents. Given psilocybin’s imminent rise in clinical and therapeutic applications for conditions such as depression, PTSD, and addiction, understanding its metabolic side effects and benefits is crucial. Obesity and metabolic syndrome often coexist with psychiatric illnesses, and current treatments rarely address both domains effectively. Psilocybin, by simultaneously modulating mood and metabolism, might represent a paradigm shift in multifaceted treatment strategies.

From a pharmacological perspective, this study revitalizes interest in serotonergic psychedelics not only as psychotherapeutics but also as agents capable of influencing fundamental biological processes like energy homeostasis. The 5-HT2A receptor’s role in regulating cortical plasticity and behavior is well established, but its downstream impact on hypothalamic circuits managing hunger and energy expenditure opens exciting avenues for drug development. Targeted agonists or modulators derived from psilocybin’s molecular scaffold could be engineered to optimize metabolic outcomes while minimizing hallucinogenic effects.

Importantly, the dose-dependent analysis in the study revealed a therapeutic window where metabolic benefits are maximized without overt behavioral disruption. This fine balance between efficacy and psychoactivity will be critical in translating findings into safe clinical protocols for humans. Furthermore, the durability of psilocybin’s effects on energy metabolism, persisting well beyond the clearance of the drug from the body, points toward lasting neural circuit remodeling that could underpin sustained therapeutic advantages.

The research also sheds light on the gut-brain axis, positively demonstrating that central effects of psilocybin may indirectly influence peripheral metabolism. Future studies are anticipated to probe the involvement of gut microbiota, enteroendocrine signals, and vagal nerve pathways in mediating the observed phenotypes. Given the dynamic crosstalk between the microbiome and host metabolism, psilocybin’s capacity to alter gut composition or function could be another layer to its multifaceted physiological actions.

Critically, the authors acknowledge limitations in translating murine data directly to humans but emphasize the robust experimental design, including controlled dosing, multiple behavioral endpoints, and complementary molecular analyses, which strengthen the study’s internal validity. They call for clinical trials evaluating metabolic endpoints in human psilocybin study participants—which could significantly influence dosing strategies for therapeutic use, particularly in populations vulnerable to metabolic dysfunction.

In conclusion, this pioneering study reveals that psilocybin exerts profound acute and long-lasting effects on energy balance and feeding behavior in mice, mediated through serotonergic receptor pathways and complex neuroendocrine gene regulation. It offers a compelling biological rationale for further exploration of psychedelics as modulators of metabolism, potentially heralding innovative treatments for obesity, eating disorders, and metabolic comorbidities of psychiatric diseases. As psychedelics transition to mainstream medicine, integrating metabolic considerations will be vital to harnessing their full therapeutic potential.

By illuminating previously unrecognized roles of psilocybin in fundamental energy physiology, this research sets the stage for a new era of psychedelic science—one that bridges neuroscience, metabolism, and psychiatry, promising holistic intervention strategies that transform patient outcomes. As the field advances, multidisciplinary collaborations will be essential to disentangle the intricate networks influenced by psilocybin, optimize clinical applications, and ensure safety in therapeutic contexts inviting profound neurobiological modulation.

Subject of Research: Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.

Article Title: Correction: Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice.

Article References:
Fadahunsi, N., Lund, J., Breum, A.W. et al. Correction: Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Transl Psychiatry 15, 466 (2025). https://doi.org/10.1038/s41398-025-03729-1

Image Credits: AI Generated

At the mechanistic heart of this innovation lies the peptide–antibody conjugate that leverages the complementary functionalities of GIPR and GLP-1R, two receptors intricately linked to glucose metabolism and energy balance. While GLP-1R agonists have already carved a niche in managing type 2 diabetes and weight loss, combining this pathway with GIPR targeting represents an evolution toward multi-receptor pharmacology that may overcome the limitations of monotherapy. The investigators meticulously demonstrate that the conjugate’s efficacy hinges on the simultaneous activation of brain GIPR and GLP-1R, highlighting the central nervous system as a critical mediator beyond peripheral receptor action.

The structural design of the GIPR-Ab/GLP-1 peptide–antibody conjugate stands out due to its innovative architecture: the conjugate couples a monoclonal antibody engineered to target GIPR with a GLP-1 peptide known for its anorectic and insulinotropic effects. This bi-functional molecule achieves enhanced receptor activation synergy in hypothalamic and other brain regions responsible for energy intake and expenditure regulation. Unlike conventional peptide therapies that have limited brain penetrance and shorter half-lives, the antibody-based delivery system potentially facilitates improved pharmacokinetics and receptor specificity, resulting in superior therapeutic outcomes in obese mice.

Central to the study’s rigor was the demonstration that the observed weight loss effects are contingent upon receptor presence in the brain, signifying a neurocentric mode of action. Knockout mouse models lacking either GIPR or GLP-1R expression within the central nervous system showed attenuated response to the conjugate, confirming that peripheral receptor activation alone is insufficient for the full therapeutic benefit. This finding challenges prevailing paradigms that predominantly attribute GLP-1R agonists’ efficacy to peripheral effects such as delayed gastric emptying and warrants a deeper exploration into neuroendocrine integration in obesity pharmacotherapy.

The research team further dissected downstream signaling cascades initiated by receptor activation, revealing enhanced cAMP production, receptor internalization dynamics, and modulation of neuronal circuits tied to appetite control. Insights into these intracellular pathways provide a molecular framework explaining the conjugate’s superior potency compared to individual receptor agonists or antibodies administered independently. These details lay the groundwork for developing next-generation peptides and antibodies optimized for dual receptor targeting, potentially transforming clinical strategies for obesity and related metabolic disorders.

Another remarkable aspect is the dual receptor engagement’s impact on energy expenditure parameters. Beyond appetite suppression, treated obese mice displayed increased thermogenesis and enhanced metabolic rates, suggesting that the conjugate fosters a holistic metabolic remodeling. The activation of brain GIPR and GLP-1R appears to amplify sympathetic nervous system signaling and brown adipose tissue activation, phenomena critical for sustained weight loss beyond mere caloric restriction.

While the translational relevance is promising, the authors cautiously discuss the challenges ahead in adapting such conjugates for human use. Considerations include ensuring brain penetrance in humans, immunogenicity of monoclonal antibodies, and fine-tuning dosing regimens to minimize adverse effects such as nausea or hypoglycemia commonly associated with GLP-1R therapies. Nevertheless, the preclinical efficacy sets a compelling precedent for advancing dual receptor combinations that harness central mechanisms.

This research exemplifies the rapidly evolving landscape of biotherapeutics, where convergence of antibody engineering and peptide pharmacology culminates in multi-target agents capable of modulating complex physiological networks. The exquisite targeting and prolonged half-life of antibody conjugates may also circumvent issues like peptide degradation and receptor desensitization, pervasive hurdles in obesity treatment development. These technological innovations herald a new class of medications that do not merely suppress appetite but reprogram neuro-metabolic pathways for sustainable weight management.

Intriguingly, the findings could extend beyond obesity to metabolic diseases intertwined with central dysfunction, such as type 2 diabetes, nonalcoholic fatty liver disease, and potentially neurodegeneration linked to metabolic stress. By delineating the brain’s essential role in mediating additive effects of GIPR and GLP-1R conjugates, this work provides a beacon for exploring central receptor co-activation in diverse pathologies with metabolic etiology.

Furthermore, the evidence suggests that personalized medicine approaches may benefit from receptor profiling in patients. Understanding individual variations in central GIPR and GLP-1R expression or sensitivity could inform tailored treatment regimens using these conjugates to maximize efficacy and minimize side effects. This personalized approach in metabolic therapeutics resonates with broader trends in precision medicine, adding another dimension to obesity care.

The study also stimulates questions about receptor cross-talk and signaling bias that merit deeper investigation. Potential differences in G protein versus β-arrestin pathway activation by the conjugate could modulate therapeutic effects and safety profiles. Advanced pharmacological characterization and structure-function analyses of receptor complexes engaged by the conjugate will be essential for refining drug design and predicting long-term outcomes.

Importantly, as obesity remains a global health crisis with escalating prevalence and limited highly effective pharmacotherapies, innovations such as the GIPR-Ab/GLP-1 conjugate offer hope for more efficacious treatment modalities. The additive weight loss observed in obese mice marks a significant milestone and supports continued exploration and investment into multifunctional agonists that transcend single receptor targeting approaches.

In sum, this landmark study by Liu, Killion, Hammoud, and colleagues sets a new benchmark in metabolic drug development by uncovering the critical requirement of brain GIPR and GLP-1R for additive weight loss mediated by an ingeniously designed peptide–antibody conjugate. By bridging structural biology, neuropharmacology, and metabolic science, the research opens pathways toward innovative, centrally acting anti-obesity therapies capable of reshaping future treatment paradigms.

As the scientific community eagerly awaits clinical validation, this work underscores the transformative potential of combining antibody technology with peptide therapeutics to harness central nervous system targets in metabolic disease. Should future studies confirm these findings in humans, we may be on the cusp of a new era where brain receptor co-activation strategies redefine effective, durable obesity interventions with broad-reaching health impacts.

Subject of Research: Brain GIPR and GLP-1R involvement in additive weight loss via a GIPR-Ab/GLP-1 peptide–antibody conjugate in obesity

Article Title: GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice

Article References:

Liu, C.M., Killion, E.A., Hammoud, R. et al. GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.
Nat Metab (2025). https://doi.org/10.1038/s42255-025-01295-w

Image Credits: AI Generated